Aktie mit hardcore Potential - 500 Beiträge pro Seite

[BrauchGeld]

Hallo

Es handelt sich dabei um das kanadische unternehmen Cipher Pharmaceuticals ich hatte die aktie schon im Depomed thread vorgestellt.Cipher Pharma ist einfach vollig unentdeckt bis jetzt .
Das Unternehmen ist übertrieben unterbewertet aber schaut euch selbst die daten an.
Sollten die produkte die zulassung erreichen sehe ich hier kurse von mindestens 10€.

Kurs:1,91c$ / ca.1,30€
Mk:40,5mio c$ / ca.27mio €
Cash:27,2mio c$ / 18,3mio €
Ist auch in Frankfurt und Berlin gelistet.


http://www.cipherpharma.com/downloads/PresentationMay2005.pd…

Pipeline:
http://www.cipherpharma.com/web/main.cfm?docID=11

cip-fenofibrate mit teilzulassung volle zulassung spätestens ende 1Q 2006. (ca.1Mrd$ Markt)
cip-isotretinoin in phase 3 --NDA-filing für diesen quartal geplant.
cip-tramadol auch in phase 3--NDA-filing 1.Q 2006(über 800mio$ Markt)


Und hier die Insiderkäufe der letzten monate:
Feb 04/05 Mar 09/04 Andrews, Larry 10 - Acquisition in the public market Common Shares 5,000 $3.120
Feb 04/05 Feb 23/04 Andrews, Larry 00 - Opening Balance-Initial SEDI Report Common Shares
Feb 03/05 Sep 17/04 Andrews, Larry 50 - Grant of options Options 250,000 $2.350
Feb 03/05 Feb 23/04 Andrews, Larry 00 - Opening Balance-Initial SEDI Report Options
Aug 31/04 Aug 26/04 Zimmerman, Waldemar 10 - Acquisition in the public market Common Shares 100 $2.350
Aug 31/04 Aug 26/04 Zimmerman, Waldemar 10 - Acquisition in the public market Common Shares 11,700 $2.427
Aug 31/04 Aug 26/04 Zimmerman, Waldemar 10 - Acquisition in the public market Common Shares 300 $2.490
Aug 31/04 Aug 26/04 Zimmerman, Waldemar 10 - Acquisition in the public market Common Shares 3,400 $2.438
Aug 31/04 Aug 26/04 Zimmerman, Waldemar 10 - Acquisition in the public market Common Shares 4,500 $2.450
Aug 20/04 Aug 19/04 Mull, John 51 - Exercise of options Common Shares 150,000 $1.020


As at March 31, 2005, Cipher had cash and cash equivalents of $27.2 million. The Company expects that these funds will be sufficient to fund drug development for approximately the current and next fiscal years.


Drug Development Update
-----------------------


In the first quarter of 2005, the FDA agreed to a revised clinical development program for Cip-tramadol, a once-daily, sustained-release formulation of the pain medication tramadol. The FDA has indicated that a successful outcome from this study, in combination with the Company`s ongoing clinical work, would provide sufficient data to support an NDA submission. The study is expected to be completed in Q4 2005, followed by an NDA submission in Q1 2006. In addition, Cipher`s six- and 12-month safety trials are expected to be completed prior to the end of Q3 2005.
During the fourth quarter of 2004, Cipher shared the findings of its pivotal (bioequivalence) studies for Cip-isotretinoin with the FDA. Cipher met with the FDA during the first quarter of 2005. Based on the FDA`s feedback, Cipher is proceeding with its NDA filing, which it expects to submit by the end of the second quarter of 2005.

Cipher is continuing with patent litigation for its lead compound, Cip-fenofibrate. The Company`s Markman (pre-trial) hearing is expected in May 2005. During the first quarter of 2005, the Federal Court of Canada ruled in favour of Cipher in its lawsuit with Fournier Pharma Inc. and Laboratories Fournier S.A. This lawsuit is based on similar patents and claims that Cipher is currently in litigation over in the U.S. market. Subsequently, Fournier has appealed the Canadian decision. A ruling is expected toward the end of 2005.


Einfach superheiß dieses Teil.

[BrauchGeld]

Und hier die vor kurzen ersten positiven daten zu Tramadol in phase3

CIPHER PHARMACEUTICALS Quick Quote: DND 1.91 (Even)

Cipher reports positive efficacy results for CIP-Tramadol
5/31/2005

- Product achieves statistical significance for targeted endpoints; data to form part of Company`s NDA submission -

MISSISSAUGA, ON, May 31, 2005 (Canada NewsWire via COMTEX) --
Cipher Pharmaceuticals Inc. (TSX: DND) today reported positive results from the 12-week efficacy component of its long-term safety trial for CIP-Tramadol, a once-daily, sustained release formulation of the pain medication tramadol. In the study, CIP-Tramadol achieved statistical significance for the targeted endpoints. The results from this study, combined with the data from the Company`s previously completed and currently ongoing Phase III trials, will form the basis of its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).

"Given that we are measuring the same clinical endpoints in our ongoing Phase III trial, we are encouraged by the statistical significance achieved in this study. These data will be an important piece of our submission to the FDA," said Larry Andrews, President of Cipher Pharmaceuticals. "The U.S. pain management market, for which this product is targeted, is growing strongly and presents a significant opportunity for our once-daily tramadol formulation."

Trial Design

------------

Cipher`s long-term safety trial was designed to have an efficacy component and a safety component. The efficacy component was a randomized, double-blind, placebo-controlled trial to assess the efficacy of CIP-Tramadol over a 12-week period in a total of 580 patients with moderate to moderately severe chronic pain. Cipher consulted with the FDA on the study design and protocol, and will use the efficacy data as part of its NDA submission.

Future Milestones

-----------------

The Company expects to complete the safety component of the long-term safety trial in the third quarter of 2005. In addition, Cipher expects to complete its ongoing Phase III clinical trial in the fourth quarter of 2005, and is targeting the first quarter of 2006 for its NDA submission.

[Plusquamperfekt]

hardcore Potential ???

Was ist denn das für eine Ausdrucksweise - also bitte !

[BrauchGeld]

sorry wollte mal was neues ausprobieren

[capten]

Dann geh arbeiten

[xxt]

Ich dachte jetzt an die Beate Uhse AG

[BrauchGeld]

Cipher Pharma ist auf guten weg sich ein grosses stück kuchen vom Tramadol-Markt abzuschneiden.
Am Mittwoch gibts eine Zahlen+konferenz da werden bestimmt einige neuigkeiten bekannt gegeben.

Cipher Pharma Turns Up Heat In Once-Daily Tramadol Race

By Andy Georgiades
Of DOW JONES NEWSWIRES

TORONTO (Dow Jones)--Cipher Pharmaceuticals Inc. (DND.T) is turning up the
heat in the race to bring a once-daily form of painkiller Tramadol to the U.S.
market.
Earlier Tuesday, it reported positive results from the efficacy component of a
long-term safety trial for its CIP-Tramadol formulation. The study was part of a
revised clinical plan resulting from meetings with the U.S. Food and Drug
Administration, said Larry Andrews, president of Cipher.
"And the efficacy endpoints achieved in this study are the ones we are going
to be focusing on in our last critical Phase III trial," he told Dow Jones.
It has been anything but smooth sailing for the once-daily Tramadol
developers, including Cipher. Both Biovail Corp. (BVF) and Labopharm Inc.
(DDS.T) have had to generate additional data for the FDA. Last year, Cipher
disclosed it had to perform more clinical work before filing for approval,
citing a "significant placebo effect," which isn`t unusual in pain trials.
"We didn`t meet all ednpoints in either (of the previous studies) but we did
achieve results that, based on discussions with the FDA, were considered to be
significant in our ultimate filing, and data we could use to support that
filing," Andrews said.
But Cipher is no longer the distant third it used to be, as the delays
encountered by Biovail and Labopharm have allowed it to catch up. Andrews said
the company plans to complete the long-term safety trials in the third quarter,
and results from its Phase III trials are due in the fourth quarter.
If all goes well, it will submit its package to the FDA in the first quarter
of 2006, and get approval in early 2007. On the other hand, Labopharm expects to
have its additional Phase III data and to make its FDA submission in the second
half of 2005, putting the two perhaps three months apart, an analyst said.
"We`re definitely in the race," Andrews said, noting that the market
opportunity is so large it will support more than one product. Andrews added
that discussions with potential licensing partners continue, and have "picked
up" in the last couple of months.
Labopharm and Biovail have made progress elsewhere with Tramadol. Labopharm
had its once-daily Tramadol approved in Europe earlier this year, and the FDA
approved Biovail`s flashdose (quick-dissolve) version of Tramadol earlier this
month.
With respect to once-daily Tramadol in the U.S., Biovail still appears to have
the edge. It expects results from its new Phase III trial in late 2005 or early
2006, but because it`s already made a submission to the FDA, the regulator has
to respond in six months (possibly less), compared to 10 months for Cipher and
Labopharm.
In Toronto Tuesday, Cipher is down 15 Canadian cents, or 7.7%, to C$1.80 on
about 87,000 shares.
The analyst said the trial data are positive for Cipher and bode well for its
ongoing Phase III studies. Although the stock is down, the analyst noted that
it`s very thinly traded and most of the shares are held by the company`s
chairman and a few institutions.
In addition, the company isn`t very well-known because it was spun out from
the CML Healthcare Income Trust (CLC.UN.T) conversion, and it didn`t go through
the initial-public-offering process, the analyst said.
--------
Notice of Cipher Pharmaceuticals Inc. Conference Call
Thursday July 28, 2:40 pm ET


- Fiscal 2005 Second Quarter Results to be Released on August 3, 2005 -
Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, July 28 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND - News), will be conducting a conference call on Wednesday, August 3 at 4:45pm, Eastern Time, to discuss its fiscal 2005 second quarter financial results and other corporate developments. Cipher invites all interested parties to participate. You can join the call by dialing 416-640-4127 or 1-800-814-4861. Please call in 15 minutes prior to the call to secure a line. You will be put on hold until the conference call begins.
Dr. John Mull, CEO, will chair the call. A question and answer session will follow, at which time the operator will direct participants as to the correct procedure for submitting questions. A taped replay of the conference call will be available until Wednesday, August 10, 2005 by calling 416-640-1917 or 1-877-289-8525, reference number 21132672. We look forward to your participation.

A live audio webcast of the conference call will be available through www.cipherpharma.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. An archived replay of the webcast will be available for 360 days.

[BrauchGeld]

Moin

Ich glaube diese Aktie ist eine Goldgrube und ich befinde mich mittendrin

Cipher reaches agreement to dismiss patent litigation in United States for CIP-Fenofibrate
06/01/2005 - Cipher Pharmaceuticals Inc. announced that it has reached an agreement with Abbott Laboratories, Fournier Industrie et Santé and Laboratoires Fournier S.A. to dismiss all claims in the U.S. patent litigation related to CIP-Fenofibrate, Cipher`s formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia, a cholesterol disorder. Terms of the settlement agreement are confidential.Advertisement


Cipher has tentative approval from the U.S. Food and Drug Administration ("FDA"), which it received in July 2004, and this agreement will allow the Company to immediately begin the process of obtaining final FDA approval. CIP-Fenofibrate is not interchangeable with other currently marketed fenofibrate formulations and will be marketed as a branded product.

"We are extremely pleased to have this behind us so we can focus our efforts entirely on final FDA approval and securing a U.S. marketing partner," said Larry Andrews, President of Cipher Pharmaceuticals. "We believe we have a competitive product for what is clearly a large and growing therapeutic segment. Fenofibrate sales reached $850 million in the U.S. last year and are forecasted to exceed $1 billion in 2005."

schönen Sonntag noch

[BrauchGeld]

Schon bald wird Cipher starten ,pech für diejenigen die nicht dabei sind.


Cipher reports fiscal 2005 second quarter results
Wednesday August 3, 4:22 pm ET


Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Aug. 3 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND - News) today announced its financial results for the three- and six-month periods ended June 30, 2005.

Q2 2005 Summary
---------------

- Reported positive results from the 12-week efficacy component of its
long-term safety trial for CIP-Tramadol, a once-daily, sustained-
release formulation of the pain medication tramadol
- Reached agreement to dismiss all claims in the U.S. patent litigation
related to CIP-Fenofibrate
- Submitted New Drug Application (NDA) to the U.S. Food and Drug
Administration (FDA) for CIP-Isotretinoin
- Strengthened management team with appointment of Dr. Kishna
Kalicharran as Vice President, Business Development
- Cash and cash equivalents of $25.9 million at quarter end


"During the second quarter we reached very important milestones for our three late-stage products, highlighted by positive results from a pivotal trial on our once-daily tramadol product and the dismissal of patent litigation in the United States for CIP-Fenofibrate, which sets the stage for final FDA approval in the second half of this year," said Larry Andrews, President of Cipher Pharmaceuticals. "We have several other key milestones ahead of us in the coming quarters, including a U.S. marketing partnership for CIP-Fenofibrate and completion of our Phase III efficacy trial for CIP-Tramadol. We are also currently evaluating several product candidates with the view to in-licensing."

Financial Review
----------------


As a result of a change in the Company`s year end to December 31 from September 30, the Company`s fiscal 2004 period was 15 months (October 1, 2003 to December 31, 2004).
Research and development (R&D) expenses for the three months ended June 30, 2005 were $4.2 million, compared with $3.9 million in the same period last year. These expenses mainly reflect the development costs for CIP-Tramadol. For the fiscal year to date, R&D expenses were $6.1 million, compared with $8.7 million for the nine-month period ended June 30, 2004. The Company expects to invest $12 to $15 million in its current pipeline products this year.

Operating, general and administrative expenses (OG&A) for the three months ended June 30, 2005 were $1.2 million, compared with $1.9 million for the comparable period in 2004. The decrease mainly reflects lower litigation costs related to CIP-Fenofibrate.

During the first quarter of 2005, Cipher sold its non-core pharmaceutical research services business, Pharma Medica Research Inc., to focus entirely on growing its core drug development business. The results of Pharma Medica are reported as a discontinued operation. For the second quarter of 2005, loss from continuing operations was $5.3 million ($0.25 per basic and diluted share), compared with loss from continuing operations of $5.6 million ($0.27 per basic and diluted share) in the same period last year. For the six months ended June 30, 2005, loss from continuing operations was $7.8 million ($0.37 per basic and diluted share). Net income for the six months ended June 30, 2005 was $0.5 million ($0.02 per basic and diluted share), which includes a $7.6 million gain on the disposal of Pharma Medica.

As at June 30, 2005, Cipher had cash and cash equivalents of $25.9 million. The Company expects these funds will be sufficient to fund current drug development plans for approximately the current year and next fiscal year. In addition, the sale of Pharma Medica included a deferred payment of $4.0 million, which is repayable to Cipher in equal annual installments over a five-year period.


Drug Development Update
-----------------------


During the second quarter, Cipher reported positive results from the 12-week efficacy component of its long-term safety trial for CIP-Tramadol, a once-daily, sustained release formulation of the pain medication tramadol. The randomized, double-blind, placebo-controlled trial assessed the efficacy of CIP-Tramadol over a 12-week period in a total of 580 patients with moderate to moderately severe chronic pain. CIP-Tramadol achieved statistical significance for the targeted endpoints. The results from this study, combined with the data from the Company`s previously completed Phase I and III trials and currently ongoing Phase III trial, will form the basis of its NDA with the FDA. The Company expects to complete its ongoing safety trial in the third quarter of 2005 and its Phase III trial in the fourth quarter of 2005.
During the second quarter, the Company announced that it reached an agreement with Abbott Laboratories, Fournier Industrie et Santé and Laboratoires Fournier S.A. to dismiss all claims in the U.S. patent litigation related to CIP-Fenofibrate. The Company expects to secure a U.S. marketing partnership and obtain final FDA approval before the end of 2005.

Cipher recently submitted an NDA for CIP-Isotretinoin, an innovative formulation of the acne medication isotretinoin. The Company anticipates that the NDA will be accepted for review by the FDA during the third quarter of 2005.

Discussions with potential commercial partners are ongoing for all three products.

[BrauchGeld]

Ist ja der wahnsinn ganze 3200 aktien wurden heute an der tsx gehandelt soviel zum bekanntheitsgrad.
Immerhin notiert jetzt die aktie bei 2C$,spätestens wenn geld in die Kasse kommt wird sich einiges ändern und das wird schon bald sein.

http://finance.yahoo.com/q?s=dnd.to

[BrauchGeld]

Hallo

Konkurrent Labopharm hat n Superdeal abgeschlossen und als nächstes ist Cipher Pharma dran.

Labopharm and Purdue Pharma Enter U.S. Licensing and Distribution Agreement for Once-Daily Tramadol
Monday August 15, 7:03 am ET


- Agreement Specifies Payments of up to US$170 Million and Royalty Rate of 20 to 25% -
LAVAL, QC, and STAMFORD, CT, Aug. 15 /CNW/ - Labopharm Inc. (TSXDS - News) and Purdue Pharma L.P. today announced a definitive licensing and distribution agreement under which Labopharm, through its subsidiary, Labopharm Europe Limited, has granted Purdue Pharma Products L.P. the exclusive right to market, sell and distribute Labopharm`s once-daily formulation of the analgesic tramadol in the United States, its territories and possessions. Labopharm will retain co-promotion rights for certain medical specialties.


"With our anticipated NDA submission later this year, our number one priority was signing a partner to allow us to commercialize our tramadol product in the world`s largest pharmaceutical market," said James R. Howard-Tripp, President and CEO, Labopharm Inc. "We are pleased not only with the terms of the agreement, which include a royalty rate commensurate with our expectations, but also with the collaborative nature of our marketing partnership. As examples, our companies will form a joint marketing team to prepare for the launch of our product. Following launch, Purdue will assist us in achieving one of our key strategic goals by building and training Labopharm`s own sales force to allow us to pursue certain specialty markets in the U.S."

Under the terms of the agreement, Labopharm will receive payments of up to US$170 million, including an up-front licensing fee of US$20 million, a payment of up to US$40 million upon regulatory approval of Labopharm`s product by the U.S. Food and Drug Administration (FDA), and payments upon the product meeting specified sales targets. Labopharm will receive royalty rates ranging from 20 to 25% of product sales. In addition, the costs of hiring, training and compensating Labopharm`s sales force will be borne by Purdue.

"There is a huge unmet need for more medications to manage pain and this once-daily formulation of tramadol may offer a valuable therapeutic option to healthcare professionals and patients with moderate to moderately severe pain," said Michael Friedman, President and Chief Executive Officer of Purdue. "Through this agreement, Purdue reinforces its leadership position in, and commitment to, pain management. Pending FDA approval of this once-daily tramadol formulation, we believe that we would be in a strong position to capture a significant portion of the tramadol market."

"As the premier U.S. marketer of long-acting pain medications, including OxyContin(R) (oxycodone HCl controlled-release) Tablets and MS Contin(R) (morphine sulfate controlled-release) Tablets, and with its extensive patent portfolio related to controlled-release tramadol, Purdue is the ideal partner for our product in the United States," said Dr. Allan Mandelzys, Vice President, Business Development, Labopharm Inc. "Purdue has a proven track record of success in the long-acting analgesic market. Prior to the launch of generic products in 2004, annual sales of OxyContin reached approximately US$2 billion."

The agreement is subject to Hart-Scott-Rodino clearance in the United States.

[BrauchGeld]

Partnernews sind in kürze zu erwarten.

CEO von Cipher Pharma:
Discussions with potential commercial partners are ongoing for all three products.



Labopharm signs up U.S. partner for Tramadol
Mon Aug 15, 2005 10:20 AM ET

TORONTO, Aug 15 (Reuters) - Labopharm Inc. (DDS.TO: Quote, Profile, Research) said on Monday it has secured a U.S. partner to market and distribute its once-daily painkiller Tramadol, which is not yet approved in the United States.

The news sent shares of Labopharm up 72 Canadian cents, or 19 percent, to C$4.52 on the Toronto Stock Exchange. The shares touched a year high of C$4.99 on Monday.

The Laval, Quebec-based drugmaker said it has granted Purdue Pharma LP, the right to market, sell and distribute the once-daily painkiller in the United States.

Labopharm is in a race with Canadian rivals Biovail Corp. (BVF.TO: Quote, Profile, Research) and Cipher Pharmaceuticals Inc. (DND.TO: Quote, Profile, Research) to bring a once-daily version of the painkiller to the U.S. market.

Labopharm has completed two late-stage clinical trials and expects to submit its new drug application to the U.S. Food and Drug Administration before the end of the year.

Under the terms of the Purdue Pharma agreement, Labopharm will receive payments of up to $170 million, including an up-front licensing fee of $20 million and a payment of up to $40 million upon U.S. regulatory approval.

Labopharm said it will receive royalty rates ranging from 20 percent to 25 percent of product sales.

[BrauchGeld]

Ist ja cool 3400 aktien reichen um Cipher 5,5% nach oben zutreiben ,kann mir sehr gut vorstellen was bei mehr volumen passieren könnte.

[BrauchGeld]

Jeden tag solche kleine sprünge wäre ich auch mit zufrieden.

http://finance.yahoo.com/q?s=dnd.to

[BrauchGeld]

Moin

Ich freue mich schon auf Donnerstag !

Cipher Pharmaceuticals to host conference call & webcast to discuss clinical studies
Friday August 19, 4:29 pm ET


- Presentation will include overview of results from pharmacokinetic studies on once-daily tramadol product -
Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Aug. 19 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND - News) today announced that it will host a conference call and webcast on Thursday, August 25, 2005 at 10:00 am (ET) to present additional information and results from its biopharmaceutical studies, including the studies on CIP-Tramadol ER, a once-daily, sustained-release formulation of the pain medication tramadol. Cipher is currently completing its Phase III clinical studies for CIP-Tramadol ER and expects to file a New Drug Application with the U.S. Food and Drug Administration in the first quarter of 2006.

Larry Andrews, President of Cipher, will chair the call. Participants can join the call by dialing 416-640-4127 or 1-800-814-4860. Please call in 15 minutes prior to the call to secure a line. You will be put on hold until the conference call begins. A question and answer session will follow, at which time the operator will direct participants as to the correct procedure for submitting questions. A taped replay of the conference call will be available until Thursday, September 1, 2005 by calling 416-640-1917 or 1-877-289-8525, reference number 21134933.

A live audio webcast, including slide presentation, will be available at www.cipherpharma.com and www.newswire.ca. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. An archived replay will be available for 360 days.

[blb]

Hast du Informationen über das Marktpotenzial der Medikamente?

[BrauchGeld]

Hallo blb

Am besten Du liest die Presentation durch da steht alles drin
http://www.cipherpharma.com/downloads/PresentationMay2005.pd…

[Mant]

hi brauchegeld!

brauche auch geld!
wir könnten einen joint venture, nein, nicht rauchen!! - probieren.
und der hardcore-pillendreher scheint ganz interessant.

hardcore-potential.
der ausdruck gefällt mir!!
(vielleicht machen die ja auch noch eine reserve-viagra! *g*)

gruss. €

[BrauchGeld]

Hallo

Hab weitere Cipher aktien gekauft bei diesen kursen blieb mir einfach nichts anderes übrig.
Diese Aktie ist einfach nur saubillig ,der Kurs liegt etwas über Cashbestand die Produkte kriegt man also praktisch gratis dazu.
Naja spätestens im ersten Quartal wissen wir mehr wenn Cip-Fenofibrate die Zulassung erhält und im zweiten Quartal steht auch schon die nächste zulassung an für Cip-Isotretinoin.
Ich glaube Cipher wird schon bald die aufmerksamkeit bekommen die es verdient bei diesen daten unvermeidlich.

Kurs:1,30C$
Cash:20mioC$
Shares out:21mio






During the third quarter of 2005 Cipher completed its six and 12-month safety trials for its once-daily formulation of tramadol. The ongoing Phase III study is expected to be completed during the first quarter of 2006. The results from this study, together with the positive results from the 12-week efficacy study completed during the second quarter and the previously completed Phase I and Phase III trials will form the basis of the Company`s NDA with the FDA which it expects to file in the first half of 2006.
Cipher expects to receive final FDA approval and secure a U.S. marketing partner for CIP-Fenofibrate by the end of the first quarter of fiscal 2006, in advance of an anticipated product launch in the first half of 2006.

The Company completed the NDA submission for CIP-Isotretinoin, an innovative formulation of the acne medication isotretinoin, during the second quarter of 2005. Subsequent to September 30, 2005, the FDA informed the Company that the NDA was accepted for review. The NDA will be reviewed under the standard 10-month review period. However, the Company believes that it still needs to address the principal issue identified in the FDA`s initial Refusal to File letter regarding CIP-Isotretinoin`s eligibility as an NDA 505(b)(2) (refer to press release dated September 6, 2005). The Company intends to work closely with the FDA during the review period to resolve any outstanding issues.

Discussions with potential commercial partners are at various stages for each of the three products with the most advanced discussions relating to CIP- Fenofibrate. The selection process of additional products to expand the pipeline also continues to advance.

[BrauchGeld]

HURRAAAAAAAAAAAAAA PARTYYYYYYYYY

Ich bin soooooo neugierig was heute passiert.
Cipher erhält die Zulassung für ein umsatz starkes produkt(1mrd$-Markt).
Die Marktkap. beträgt nur 27mio€ und in 4-5 monaten wird hoffentlich das zweite produkt zugelassen.
Ob ich schon den Sekt holen soll ?

Cipher receives FDA approval for CIP-Fenofibrate
Friday January 13, 7:01 am ET


Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Jan. 13 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND - News) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for CIP-Fenofibrate, the Company`s novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia. CIP-Fenofibrate, approved under the label as Lipofen(TM), targets a large and growing market as the three existing novel fenofibrate formulations are forecasted to exceed $1 billion in annual U.S. sales.

"CIP-Fenofibrate is the first product from our pipeline to successfully receive FDA approval and we are actively pursuing opportunities to secure a U.S. commercial distribution agreement," said Larry Andrews, President of Cipher Pharmaceuticals. "CIP-Fenofibrate is one of three late-stage products in our pipeline. With an application for CIP-Isotretinoin under review with the FDA and preparations underway to file the CIP-Tramadol application with the FDA in the first half of 2006, we believe that the approval of CIP-Fenofibrate represents the first of a number of significant milestone events for Cipher."

CIP-Fenofibrate received approval for three unique fenofibrate dosages: 50, 100 and 150 mg, with the 150 mg strength equivalent to Tricor(R) 160 mg under fed conditions. With CIP-Fenofibrate, the extent of absorption is increased under high-fat conditions relative to low-fat conditions.

The approval provides for the use of CIP-Fenofibrate as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total-cholesterol (Total-C), triglycerides, apolipoprotein B (Apo B), and to increase high-density lipoprotein (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Frederickson Type IIa, IIb) in addition to the treatment of adult patients with hypertriglyceridemia (Frederickson Types IV and V hyperlipidemia).

[schmacki]

[BrauchGeld]

Moin

Cipher Pharma ist jetzt doppelt so teuer wie vor einigen tagen und trotzdem immer noch krass unterbewertet mit knapp 60mio C$(~43mio€) cashbestand liegt bei 20mioC$(~14mio€).
Ende Juli soll das zweite produkt auf dem Markt kommen und mit Tramadol das dritte produkt anfang 2007.
Ich bin froh das ich mir vorher noch einige stücke zu sehr günstigen kursen ergattert habe.
Ob wir schon bald zweistellige kurse sehen werden,mich würde das nicht wundern.
Die Party wird also garantiert weiter gehen.

UPDATE 1-FDA approves Cipher`s cholesterol treatment
Fri Jan 13, 2006 07:34 AM ET
TORONTO, Jan 13 (Reuters) - Cipher Pharmaceuticals Inc. (DND.TO: Quote, Profile, Research) said on Friday it received final approval from the U.S. health regulators for its cholesterol treatment, marking the first FDA approval for the small Canadian company.
The Mississauga, Ontario-based company said Food and Drug Administration had given it approval for its Lipofen brand in three different dosages. The drug is used in conjunction with diet to help lower cholesterol.

The company said it was pursuing opportunities for a U.S. commercial distribution agreement.

Cipher also said its CIP-Isotretinoin to treat severe acne is under review with the FDA, and preparations were underway to file an application for its CIP-Tramadol, a painkiller, with the FDA in the first half of 2006.

Cipher`s stock closed on the Toronto Stock Exchange on Thursday at C$1.82.

[schmacki]

Bin ab heute mit an Bord,fehlt nur noch der Vertriebspartner!

[BrauchGeld]

Nabend

Das Interesse an Cipher steigt!

www.streetinvesting.com: Begins Research on Cipher Pharmaceuticals Inc.
1/17/2006

Jan 17, 2006 (M2 PRESSWIRE via COMTEX) --
Streetinvesting.com, and our professional research team, will be following the progress of Cipher Pharmaceuticals Inc.(TSXND) over the next few months in the hopes of finding out if a recent U.S. FDA approval could benefit shareholders. After reviewing the proceeding information, our team of researchers will be monitoring Cipher throughout the ensuing months in the hopes that we will see more results like the explosive gains exhibited thus far in January. Streetinvesting.com strives to bring true growth opportunities directly to its valued subscribers. Our strength lies in finding these undervalued and under-marketed companies and delivering our research in a timely manner. Streetinvesting.com will be tracking this company attentively for the subsequent weeks and keep interested investors and shareholders posted on any new findings and behind-the-scenes update. For a complimentary and comprehensive report on our current analysis and opinions, please visit www.streetinvesting.com for a free membership subscription.

Cipher Pharmaceuticals Inc. is an innovative drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies.

Cipher`s strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which, the products are out-licensed to international partners. Because Cipher`s products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines, and significantly lower development costs. Integral to this strategy is the strength of the Company`s partnerships, as well as the management team`s experience in product selection, licensing, pharmaceutical portfolio management, as well as clinical and regulatory affairs.

Cipher currently has three late-stage drugs in its clinical development pipeline. The Company`s lead compound, CIP-Fenofibrate, received final approval from the U.S. Food and Drug Administration earlier this month. In addition, Cipher is developing formulations of the pain reliever tramadol and the acne treatment isotretinoin.

Cipher was originally the pharmaceutical division of CML Healthcare Inc., one of Canada`s largest healthcare services businesses. However, it became a separate public company in February of 2004.

On Jan 13th, Cipher Pharmaceuticals Inc. was pleased to announce that it had received final approval from the U.S. Food and Drug Administration, or FDA, for CIP-Fenofibrate. CIP-Fenofibrate is the Company`s novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia, more commonly known as high cholesterol. CIP-Fenofibrate, approved under the label as Lipofen, targets a large and growing market as the three existing novel fenofibrate formulations are forecasted to exceed $1 billion in annual U.S. sales.

There are two main....

To continue with the more in-depth analysis, please visit www.streetinvesting.com for a complimentary subscription to access this report and other related articles. Please note that membership does not require credit card information.

All material herein was prepared by Streetinvesting.com, (Street Investing) based upon information believed to be reliable. The information contained herein is not guaranteed by Streetinvesting.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Streetinvesting.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Streetinvesting.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Streetinvesting.com`s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.

Streetinvesting.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies` annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Streetinvesting.com undertakes no obligation to update such statements.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

-------------------------------------------------

RESEARCHALERT-Clarus ups Cipher share price target
Tue Jan 17, 2006 11:24 AM ET
TORONTO, Jan 17 (Reuters) - Clarus Securities Inc. on Tuesday boosted its share price target for Cipher Pharmaceuticals Inc. (DND.TO: Quote, Profile, Research) , following recent U.S. Food and Drug Administration approval of one of Cipher`s key treatments.
Clarus analyst Trevor Li raised the small biotechnology company`s 12-month share price target to C$3.25 a share from C$2.50 previously, while maintaining a "Speculative Buy" rating on the stock.

Cipher was down 9 Canadian cents at C$2.51 on the Toronto Stock Exchange.

The small Canadian company last week won final approval from the U.S. Food and Drug Administration for its cholesterol treatment.

The company said it was also pursuing opportunities for a U.S. commercial distribution agreement.

"We are encouraged by the final approval by the FDA on Lipofen as the company shifts to the negotiations for a U.S. marketing partner," Li wrote in a report.

"With the significant price appreciation in recent trading sessions, the stock could experience some additional volatility. However, we expect a number of near-term catalysts will add further fuel to the stock."

[BrauchGeld]

Hallo

Noch kann man günstig kaufen ,fragt sich nur noch wie lange.

Strong Buy hoch 10

[BrauchGeld]

Hallo

News und Cipher schliesst zum ersten mal über der 3C$ marke was sehr positiv ist.
Die Party geht weiter.....


Cipher provides CIP-Tramadol ER update
Thursday January 26, 4:12 pm ET


- Company expects to file NDA in second quarter of 2006 -
Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Jan. 26 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND - News) today updated the market on its clinical and regulatory progress and its expected milestones for CIP-Tramadol Extended Release (ER), its once-daily, sustained release formulation of the pain medication tramadol. Cipher expects to file the New Drug Application with the U.S. Food and Drug Administration (FDA) in the second quarter of 2006. Cipher has been advised by the FDA that its existing clinical data package meets the requirements to file a NDA.


"The fact that our existing data meets the requirements to file with the FDA now allows us to complete the preparation of the submission and moves us one step closer toward commercialization of CIP-Tramadol ER," commented Larry Andrews, President of Cipher Pharmaceuticals Inc. "We intend to complete our ongoing Phase III study to further support both the regulatory and commercial success of the product."

The submission of the NDA application in the second quarter of 2006 is consistent with the update the Company provided as part of its third quarter report. Meanwhile the Company has completed enrollment of its ongoing Phase III efficacy trial (the 02.05 trial) of CIP-Tramadol ER. The Company expects results from the Phase III trial to be available in the third quarter of 2006 along with results from a Phase I trial to investigate the potential for a clinically relevant interaction between CIP-Tramadol ER and high levels of alcohol.

In biopharmaceutical trials, Cipher`s capsule formulation of tramadol has demonstrated both rapid absorption and an extended release profile over a 24-hour timeframe. It has also demonstrated comparable bioavailability under both fed and fasted conditions, which will allow the product to be taken without regard to meals.

[schmacki]

Einfach nur geil!!!

[schmacki]

Das ist ja wirklich ein Goldesel

[BrauchGeld]

@schmacki

Die Aktie wird uns noch sehr viel freude machen,es gab genug gelegenheiten noch günstig einzusteigen.


Partyyyyyyyyyyyyyyy

[schmacki]

Sehr geringe MK,lass da mal einen Deal mit einem namhaften Pharmakonzern zustande kommen...

[BrauchGeld]

Cipher schliesst bei 3,80C$ über 24%plus.
Die Marktkap.beträgt jetzt immer noch lächerliche 80,6mioC$ oder ~58mio€.

Pipeline:

Cip-Fenofibrate (cholesterol treatment)Markt:1Mrd US$ seit 13.01.06 zugelassen.

Cip-Isotretinoin (Severe Acne) zulassung ende juli 06.

Cip-Tramadol (moderate to severe pain)Markt:über 1Mrd US$
zulassung 2Q 2007

Das wird sicher ein schönes Jahr für Cipher und für mich

Gute Nacht und ein schönes Wochenende

[BrauchGeld]

Hallo

Cipher kennt kein halten mehr,heute ist die 4 C$ gefallen und ein ende ist noch lange nicht in sicht.


3M Chart:


5D Chart:

[schmacki]

Die Aktie ist stark,auch nach so einem Anstieg,geht weiter!

[schmacki]

Partyyyyy!!!

[BrauchGeld]

Du sagst es Partyyyyyyyyyy

Ob heute noch die 5 C$ fällt ? Wir werden es sehen gooo Cipher goooooo

[schmacki]

Hallo!
Habe im C-Board gelesen das der Ceo von Cipher 44% der Aktien hält.Wenn das stimmt wären nur ca.12 Mill.im Freefloat!
Gruss

[schmacki]

Wo werden wir landen?

[BrauchGeld]

Nicht zu glauben diese beschiessene analysten von Global Biotech(GBI) haben meine Cipher Pharma entdeckt.
Naja egal hauptsache die Aktie wird in die höhe getrieben.

Cipher Pharmaceuticals für Spekulative

06.02.2006
Global Biotech Investing

Spekulative Anleger springen umgehend mit einer kleinen Startposition auf die Cipher Pharmaceuticals-Aktie (ISIN CA17253X1050 / WKN A0B85L) auf, im deutschen Handel aber unbedingt limitieren, raten die Experten von "Global Biotech Investing".

Das Unternehmen habe Mitte Januar die endgültige Vertriebsfreigabe für den Cholesterin-Senker Lipofen von den US-Gesundheitsbehörden erhalten. Dies sei das erste Präparat, welches die Gesellschaft auf dem Markt habe. Als nächstes wolle Cipher Pharmaceuticals nun so schnell wie möglich eine Vertriebsvereinbarung

Mit CIP-Isotretinion und CIP-Tramadol habe die Gesellschaft noch zwei weitere interessante Mittel in der Produktpipeline. Für CIP-Isotretinion werde ein FDA-Entscheid spätestens bis zum 01. Mai erwartet.

Das Investmenthaus Clarus Securities prognostiziere im kommenden Jahr ein EPS in Höhe von 0,60 Kanadische Dollar. Damit wäre der Titel - trotz der jüngsten Kursrally - lediglich mit einem KGV 2007e von 9 bewertet.

Spekulative Anleger springen umgehend mit einer kleinen Startposition auf die Cipher Pharmaceuticals-Aktie auf, im deutschen Handel aber unbedingt limitieren, raten die Experten von "Global Biotech Investing".

[BrauchGeld]

Hallo

Korrektur scheint endlich vorbei zu sein ,gestern gings schon wieder um knapp 15% aufwärts .
Die Aktie ist trotz starken anstieg immer noch krass unterbewertet .
Mein Kurzziel liegt zwischen 10-15 C$ für dieses Jahr,und das ist noch eine konservative einschätzung.

[BrauchGeld]

Moin

Die Aktie hält sich gut über 5C$ ,Ath liegt bei 5,25C$ und es sieht aus als wäre heute ein guter zeitpunkt neue highs zu erklimmen.
Nach USA erhält jetzt Cipher die Zulassung für Fenofibrate in Canada.
News kam gestern nachbörslich deshalb wird Cipher erst heute drauf reagieren .

Cipher receives Health Canada approval of CIP-Fenofibrate
Monday February 20, 5:01 pm ET


Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Feb. 20 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND - News) today announced that it has received final approval from Health Canada for CIP-Fenofibrate, the Company`s novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia. Health Canada has issued a Notice of Compliance for CIP-Fenofibrate which allows for the product to be marketed in Canada. The notification came after the Federal Court of Canada advised the Company it would dismiss the legal proceedings brought by Fournier-Pharma Inc. and Laboratoires Fournier S.A. related to the second of two patent issues. The dismissal cleared the path for Health Canada to issue final approval for CIP-Fenofibrate. Cipher announced in January 2006 that it received final approval for CIP-Fenofibrate in the United States from the U.S. Food and Drug Administration.

"We are pleased to have this important milestone behind us," commented Larry Andrews, President of Cipher Pharmaceuticals Inc. "The approval from Health Canada clears the path to market for CIP-Fenofibrate and will allow ongoing discussions with interested commercial partners for Canada to proceed."

In April 2004, the Therapeutic Products Directorate of the Canadian Health Protection Branch completed its review of Cipher`s new drug submission for its novel formulation of CIP-Fenofibrate, and confirmed there were no outstanding review issues. Health Canada approval for CIP-Fenofibrate had been on hold since that time pending the outcome of the legal proceedings.

The first patent case brought forward by Fournier-Pharma Inc. and Laboratoires Fournier S.A. ("Fournier") in March 2003 under the Patented Medicines (Notice of Compliance) Regulations related to Canadian Patent No. 2,219,475 (the "475 Patent") and LIPIDIL SUPRA 100 mg and 160 mg fenofibrate tablets. During the first quarter of 2005, the Federal Court of Canada ruled in favour of Cipher. Just prior to that trial ruling, Fournier listed a second patent, Canadian Patent No. 2,372,576 (the "576 Patent") on the Patent Registry and brought forward a second proceeding. Fournier subsequently appealed the 475 Patent decision. That appeal was dismissed by the Federal Court of Appeal on October 11, 2005 with costs awarded to Cipher.

The most recent decision from the Federal Court of Canada relates to the 576 Patent. On its motion for a dismissal, Cipher was able to convince the Federal Court that Fournier had not made out a case that justified proceeding to trial. The presiding Prothonotary of the Federal Court stated that she was granting the motion to dismiss, with an Order and reasons to follow, which has allowed Health Canada to provide final approval of CIP-Fenofibrate.

[BrauchGeld]

Jetzt heisst es daumen drücken und auf das beste hoffen.

Market Regulation Services - Trading Halt - Cipher Pharmaceuticals Inc - DND
Wednesday February 22, 3:22 pm ET


TORONTO, Feb. 22 /CNW/ - The following issues have been halted by Market Regulation Services (RS):

Issuer Name: Cipher Pharmaceuticals Inc
TSX Ticker Symbol: DND
Time of Halt: 15:11 EST
Reason for Halt: Pending News

For further information

[schmacki]

Was kann da kommen,Übernahmeangebot?

[schmacki]

Cipher Announces $12 Million Bought Deal
NEWS RELEASE TRANSMITTED BY CCNMATTHEWS

Cipher Pharmaceuticals Inc.

February 22, 2006 - 15:43:29 ET

Cipher Announces $12 Million Bought Deal


MISSISSAUGA, ONTARIO--(CCNMatthews - Feb. 22, 2006) -

NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR DISSEMINATION IN THE UNITED
STATES

Cipher Pharmaceuticals Inc. (TSXND) today announced that it has entered into
an agreement for a $12 million bought deal financing with a syndicate of
underwriters led by National Bank Financial Inc. A total of 2.5 million Common
Shares will be issued at a price of $4.80 per common share. The proceeds from
the offering will be used to expand the Company`s product pipeline and for
general corporate purposes.

The underwriters will also have an option, exercisable at any time until up to
30 days following the Closing of the financing, to purchase up to an
additional 15% of the offering on the same terms and conditions which would
increase the total amount to $13.8 million. The offering is subject to normal
regulatory approvals including approval of the Toronto Stock Exchange and is
expected to close on or before March 14, 2006.

The securities offered have not been registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold within the
United States absent registrations or an exemption from the registration
requirements. This release does not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of the securities
in any State in which such offer, solicitation or sale would be unlawful.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a drug development company focused on
commercializing novel formulations of successful, currently marketed molecules
using advanced drug delivery technologies. Cipher`s strategy is to in-license
products that incorporate proven drug delivery technologies and advance them
through the clinical development and regulatory approval stages, after which
the products are out-licensed to international partners. Because Cipher`s
products are based on proven technology platforms applied to currently
marketed drugs, they are expected to have lower approval risk, shorter
development timelines and significantly lower development costs. Cipher
currently has three late-stage drugs in its pipeline. The Company`s lead
compound, CIP-Fenofibrate, received final approval from the U.S. Food and Drug
Administration and Health Canada in the first quarter of 2006. In addition,
Cipher is developing formulations of the pain reliever tramadol and the acne
treatment isotretinoin.

Cipher is listed on the Toronto Stock Exchange under the symbol `DND` and has
approximately 21 million shares outstanding. For more information, please
visit www.cipherpharma.com.

Statements made in this news release, other than those concerning historical
financial information, should be considered forward-looking and subject to
various risks and uncertainties. Such forward-looking statements are based on
management`s beliefs and assumptions regarding the information currently
available. The Company`s actual results could differ materially from those
expressed in the forward-looking statements. Factors that could cause results
to vary include, among other things, those expressed in the Company`s filings
with Canadian securities regulatory authorities. All information presented
herein should be read in conjunction with such filings.

FOR FURTHER INFORMATION PLEASE CONTACT:

The Equicom Group Ross Marshall Investor Relations [phone] ext 238
[phone] [e-mail] Cipher Pharmaceuticals Larry
Andrews President [phone] ext 24 [phone]
[e-mail]

[BrauchGeld]

Das sind gute Nachrichten die aktien werden zu 4,80 C$ rausgegeben nahe am Kurs (5,05 C$)nach abschluß dürfte es weiter aufwärts gehen.
Nach wie vor ein Sehr gutes Investment !

Fact Sheets:
http://www.cipherpharma.com/downloads/Factsheet.pdf

[BrauchGeld]

Die aktuelle Marktkap. beträgt 78 mio€ oder 107 mioC$ das ist immer noch viel zu niedrig für ein Unternehmen das bis zum 2Q 2007 drei produkte am Markt haben wird.

[schmacki]

Kaufen und liegenlassen!!!

[BrauchGeld]

Gestern gabs zahlen bisher läuft alles wunderbar.
Cipher ist super stabil bei 4,80 C$ ,trotz 400% kurssteigerung ist jede menge potential vorhanden.

Hier ein update von gestern

Drug Development Update

Subsequent to year end, Cipher announced that the FDA had advised the Company that its existing clinical package for CIP-TRAMADOL ER, a once-daily sustained-release formulation of the pain medication tramadol, meets the requirements to submit a NDA. Cipher expects to submit the NDA with the FDA in the second quarter of 2006. Meanwhile the Company plans to complete its ongoing Phase III efficacy trial (the 02.05 trial) of CIP-TRAMADOL ER to further support both the regulatory and commercial success of the product. The Company expects to complete the Phase III trial in the second quarter of 2006. Cipher also expects to complete a Phase I trial in the third quarter to investigate the potential for a clinically relevant interaction between CIP-TRAMADOL ER and high levels of alcohol that it will submit to the FDA upon completion.
Subsequent to year end, Cipher received final approval from the FDA and Health Canada for CIP-FENOFIBRATE, the Company`s novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia. CIP-FENOFIBRATE was approved by the FDA under the label as Lipofen(TM).

The Company completed the NDA submission for CIP-ISOTRETINOIN, an innovative formulation of the acne medication isotretinoin, during the second quarter of 2005. In September 2005, the Company received a Refusal to File letter from the FDA related to the eligibility of CIP-ISOTRETINOIN as an NDA 505(b)(2). Subsequently in October 2005, the NDA was accepted for review by the FDA. The NDA will be reviewed under the standard 10-month review period. The action date under the Prescription Drug User Fee Act (PDUFA) for the CIP-ISOTRETINOIN NDA is May 1, 2006. However, the Company believes that it still needs to address the issue identified in the FDA`s Refusal to File letter. The Company intends to work closely with the FDA during the review period to resolve any outstanding issues.

Discussions with potential commercial partners are at various stages for each of the three products with priority being given to CIP-FENOFIBRATE. The selection process of additional products to expand the pipeline also continues to advance.

[BrauchGeld]

Mein "sleeper" könnte nächste woche wieder unter den topperformer gehören es stehen jede menge news für dieses quartal an.
Es geht gleich am Montag los da könnte ciphers zweite produkt cip-isotretinoin(400 mio$ markt)zugelassen werden.
Für cip-fenofibrate(1 Mrd$ markt) fehlt noch ein vertriebspartner für usa.
Und zu guter letzt wird der zulassungsantrag für cip-tramadol(1 Mrd$ markt) bei der FDA eingereicht.
Die kanadier interessieren sich momentan kaum für biotechs sind viel mehr auf öl und mining werte fixiert.
Die Marktkap. beträgt immer noch lächerliche 74 mio€ cashanteil liegt bei 20 mio€.
Mein kursziel liegt immer noch im zweistelligen bereich momentan gerade mal für 4,30 C$ oder ca. 3€.
Diese Aktie ist ein Strong Buy der besonderen art.



MISSISSAUGA, ON, April 12 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced it has completed an agreement with Oryx Pharmaceuticals Inc., a privately-owned specialty pharmaceutical company, to market and distribute CIP-FENOFIBRATE in Canada. CIP-FENOFIBRATE is Cipher's novel formulation of the active ingredient fenofibrate. Terms of the deal were not disclosed.
"Oryx's focus on cardiovascular and lipid lowering markets is a ideal fit for Cipher," said Larry Andrews, President of Cipher Pharmaceuticals Inc. "Oryx's other two lipid lowering products Niaspan(R) and Advicor(R), both licensed in from U.S. based KOS Pharmaceuticals Inc. are complementary in terms of lipid coverage and will provide an attractive offering for Canadian physicians."

"We are extremely pleased to be licensing CIP-FENOFIBRATE from Cipher and look forward to adding it to our expanding portfolio of cardiovascular products," commented Douglas Reynolds, President of Oryx Pharmaceuticals Inc.

Cipher received final approval for CIP-FENOFIBRATE from Health Canada in February, 2006 and more recently received notice that CIP-FENOFIBRATE's Canadian patent application has been allowed. CIP-FENOFIBRATE will be available in Canada in 100 mg and 160 mg capsule dosages for use in the treatment of hyperlipidemia. The Canadian launch of the product is expected in Q3 2006 and revenues generated will be shared with Cipher's technology partner Galephar Pharmaceutical Research. The Canadian fenofibrate market achieved sales of Cdn$71 million in 2005 according to IMS.



Cipher Pharmaceuticals Inc. (DND) As of April 28th, 2006
Filing Date Transaction Date Insider Name Nature of transaction Securities # or value acquired or disposed of Unit Price
Mar 31/06 Mar 23/06 Garriock, William Charles 50 - Grant of options Options 20,000 $4.120
Mar 31/06 Feb 23/04 Garriock, William Charles 00 - Opening Balance-Initial SEDI Report Options
Mar 30/06 Aug 03/05 Wiseman, Stephen R. 00 - Opening Balance-Initial SEDI Report Common Shares
Mar 30/06 Aug 03/05 Wiseman, Stephen R. 00 - Opening Balance-Initial SEDI Report Common Shares
Mar 30/06 Mar 23/06 McDole, Gerald P. 50 - Grant of options Options 20,000 $4.120
Mar 30/06 Feb 23/04 McDole, Gerald P. 00 - Opening Balance-Initial SEDI Report Options
Mar 30/06 Mar 23/06 Mull, John 50 - Grant of options Options 20,000 $4.120
Mar 29/06 Mar 23/06 Zimmerman, Waldemar 50 - Grant of options Options 20,000 $4.120
Mar 29/06 Mar 23/06 Wiseman, Stephen R. 50 - Grant of options Options 20,000 $4.120
Mar 29/06 Aug 03/05 Wiseman, Stephen R. 00 - Opening Balance-Initial SEDI Report Options

[schmacki]

Wiedermal Partytime!!!

[BrauchGeld]

Antwort auf Beitrag Nr.: 21.404.771 von schmacki am 02.05.06 17:11:31

Immernoch eine sehr aussichtsreiche Aktie !

Präsentation August 2006
http://www.cipherpharma.com/downloads/DND_Presentation_Augus…
2006 Milestones

Folgender abschnitt ist erfolgreich abgeschlossen:

Final FDA and Health Canada approval
for CIP-FENOFIBRATE
Advised existing CIP-TRAMADOL ER clinical package
meets requirements to submit an NDA
Canadian marketing partner for CIP-FENOFIBRATE Q2 ’06
NDA submission for CIP-TRAMADOL ER Q2 ’06

News die noch zu erwarten sind:

U.S. marketing partner for CIP-FENOFIBRATE (Lipofen) H2 ’06
Final FDA approval for CIP-ISOTRETINOIN 2006-07
Marketing partner for CIP-ISOTRETINOIN (U.S.) 2006
Expand pipeline 2006

[mao_1]

-27% heute ist schon wirklich hardcore. Der Chart sieht jetzt alles andere als vertrauenserweckend aus

Gibt es Meinungen zur heutigen Meldung?